bluebird bio
NEWS
Bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Medigene and bluebird bio announced they are expanding a strategic research and development collaboration inked in September 2016.
Bluebird has been chosen to receive the Cooley Anemia Foundation’s Humanitarian of the Year Award at its annual gala in June.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
A look at three small biotechs that big drugmakers are drooling over.
Here are five possible acquisition targets to keep an eye on.
JOBS
IN THE PRESS
New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia
bluebird bio, Inc. announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY.
Company hosting Analyst Day on May 9, 2019 focused on research and commercial strategies
The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects.
bluebird bio, Inc., has appointed Joanne Smith-Farrell, Ph.D., to chief business officer.
First gene therapy recommended for approval in the EU for TDT
A third party press release was issued stating that the EMA issued an approval for the conditional Marketing Authorization Application for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia.
Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio’s capabilities to manufacture products for clinical development and commercial supply
bluebird bio, Inc. announced that members of the management team will present at the following upcoming investor conferences
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.